| Low-protein, low-phosphorus therapeutic diets (TDs) are often recommended for cats (Felis catus) with chronic kidney disease (CKD) in an attempt to slow disease progression. Studies in humans with CKD reveal that dietary supplementation with certain amino acids slows or prevents time-related increases in blood-serum creatinine concentration (SCr) and phosphate concentration (PHOS). The objectives of this study were to assess the influence of a renoprotective amino acid and a dipeptide complex (AB070597) on disease progression, PHOS, and protein oxidation/nitrogen-balance in non-protein, non-phosphorus-restricted diet cats with CKD. The treatment group included 67 privately-owned domestic cats with SCr and clinical signs consistent with CKD. A retrospective control group included 57 non-AB070597-treated CKD cats. Cats in the treatment group received 300-mg oral bi-daily doses of AB070597 for up to 104 weeks. SCr and PHOS were measured at approximate 12-week intervals.Treated cats experienced significantly reduced SCr (mg/dL) from baseline during all observation periods (P≤0.004), except week 12 (P=0.054). The overall least squares mean (LS-mean) difference between treatment and control groups was -0.5 (P<0.001). When International Renal Interest Society (IRIS) disease stage was expressed as LS-means change-frombaseline, treatment values were negative, whereas control values were positive, indicating a decline in stage for treatment and an increase for controls. The overall difference at 104 weeks for treatment was -0.4 (P<0.001). Treatment group mean and median PHOS (mg/dL) declined from baseline -1.3 (P < 0.002) and -0.2 (P <0.002), respectively, at 104 weeks, whereas control group mean and median values increased 0.14 (P<0.004) and 0.3 (P<0.002), respectively. Treatment group cats' body weights (kg, standard deviation [SD]) remained stable: mean change (0.0, 0.75), P<0.001; while controls lost weight: mean change (-0.9, 1.07), P <0.001.Oral supplementation of renoprotective amino acids and a specific dipeptide prevented disease progression, maintained nutritional status, and preserved PHOS homeostasis in treated cats and may benefit the greater population of companion cats diagnosed with CKD.
INTRODUCTION
T he prevalence of CKD rises with age, and approximately 5%, 7-10 years old, 10%,11-14 years old, and 30% of cats over 14 years of age develop CKD (Polzin et al., 1992) . The mean age at diagnosis is 12.8 years (Boyd et al., 2008) ; however, cats have been diagnosed with CKD as early as 9 months and as late as 22 years (DiBartola et al., 1987) . The course of the disease is variable, with some cats progressing to end-stage within months while others survive for years (Chakrabarti et al., 2012) . Medical consensus considers CKD progressive and irreversible, 1 <1.6 <140 Non-azotemic, but has at least one renal abnormality such as proteinuria, low urine specific gravity or abnormal imaging results. thus treatments are supportive or palliative. Treatments may include hydration maintenance, calcium, vitamin D, erythropoietin supplementation; TDs, enteral phosphate binders, anti-hypertensive therapy, and histamine H2-receptor blockers to manage secondary gastritis. The IRIS developed guidelines to categorize the severity of CKD (IRIS, 2016) . The initial assessment is based on at least 2 measurements of fasting SCr, patient history, and the results of clinical examination. The IRIS stages are shown in Table 1 .
Veterinarians often recommend TDs for cats with CKD. Restriction reduces PHOS, blood-urea nitrogen, and parathyroid hormone concentrations, and increases survival time in cats that accept the diet, when compared with cats on non-TDs (Elliot et al., 2000) . Poor acceptance is common, however; with one study showing that 59.13% of cats rejected change from their former diet to TDs (Caney, 2017) . TDs generally have decreased protein, phosphorus, increased carbohydrate, and variable fat content, compared with non-TDs.
A study by Salaun et al. (2017) confirmed an earlier finding by Hewson-Hughes et al. (2011) that a carbohydrate-consumption ceiling exists in cats which limits daily food intake based on daily carbohydrate intake; thereby creating deficits in protein and fat consumption, compared to their metabolic energy requirement, when fed high carbohydrate foods. Once they consumed food equivalent to 3 g carbohydrate/kg body-weight/day, they stopped eating.The carbohydrate-consumption ceiling established by Hewson-Hughes et al. was higher at 4.1 g carbohydrate/ kg body-weight/day.
In a study by Bryan Kestenbaum et al. (2005) of humans with CKD, PHOS was independently and significantly related to mortality. For each 1mg/dL PHOS increase, there was a significant 23% increased risk of death (P < 0.001, 95% CI, 1.12-1.36). PHOS above the mid-range value of 3.5 mg/dL correlated with increased mortality risk, with an approximately linear relation for increased risk for each 0.5 mg/dL PHOS increase.
Cats with CKD that experience a PHOS increase of 1 mg/ dL, within 1 year of diagnosis, have a 41% increased risk of progression to higher IRIS stages (Chakrabarti et al., 2012) and an 11.8% increase in the risk of death for the same increase over any time period. In a study by Boyd et al. (2008) , PHOS was the only biochemical parameter that was predictive of survival.
Inorganic phosphate (Pi) absorption and reabsorption/excretion in all mammals are controlled by 3 Na+-dependent Pi cotransporter proteins (NaPiIIb, which mediates absorption in the small intestines, and NaPi-IIa and NaPiIIc, which control reabsorption/excretion in renal proximal tubules (Foster et al., 2006) , so knowledge regarding PHOS homeostasis gained from studies in rodents and humans can apply to cats.
Regardless of the inciting cause, CKD evolves to progressive tubulointerstitial fibrosis accompanied by deteriorating renal function. L-carnosine, the dipeptide in AB070597, has been shown to increase bone morphogenetic protein-7 (BMP-7) gene expression in human periodontal ligament cells (Ito-Kato et al., 2004) . Zeisberg et al. (2003) demonstrated that BMP-7 counteracts transforming growth factor-B1-induced epithelial-to-mesenchymal transition and reverses chronic kidney injury. Our laboratory organized an in vitro microarray experiment using human renal primary proximal tubule epithelial cells (hRPTEC) (feline cells were not available) that showed cells incubated with L-carnosine at 1.763 ug/mL increased BMP-7 messenger ribonucleic acid (mRNA) expression 2.13-fold while cells incubated with AB070597 at 3.125 ug/mL showed a 3.29fold increase. L-carnosine blood-serum concentration in healthy cats is 10.17 ug/mL (Sabatino et al., 2013) .
Studies of humans with CKD demonstrate that dietary supplementation with certain amino acids and keto-amino acids slows or prevents time-related SCr increase, disease progression, and significantly reduces PHOS in some patients (Yatzidis, 2004; Mitch et al., 1984) . Further studies in humans and animals have determined that specific amino acids produce a protective effect on renal function; these include L-arginine (Reyes et al., 1994) , L-aspartic acid (Tada et al., 2008) , L-glutamic acid (Yatzidis, 2002) , L-glutamine (Sadar et al., 2016 ), glycine (Yin et al., 2002 , L-histidine (Watanabe et al., 2008) , and the dipeptide L-carnosine (β alanyl-histidine) (Aldini et al., 2011) .
AB070597 is a complex of these amino acids and dipeptide. A previous study of oral AB070597 supplementation to 27 cats with CKD showed a significant decrease in median SCr and lower median disease severity as assessed by IRIS Stage, compared with untreated controls (Archer, 2015) . The objectives of this study were to assess the influence of the amino acids and dipeptide in AB070597 on disease progression, protein oxidation/nitrogen balance, and PHOS in cats with CKD fed non-protein and non-phosphorus-restricted diets.
MATERIALS AND METHODS cats
This study was open-ended. Qualified subjects entered as they became available from referring clinics; therefore, baseline and successive observation period ( A retrospective control group of 57 non-treated CKD cats, that ranged in age from 3 to 20 years (median = 13 years) and weighed 4.1 (1.6) kg, was selected from medical records at 5 participating clinics (A, B, C, D, E.). Cats and their respective IRIS stages were distributed at clinics as follows: A = 20 stage 2, 4 stage 4 B = 7 stage 2, 4 stage 3, 2 stage 4 C = 6 stage 2, 4 stage 3 D = 2 stage 2, 1 stage 4 E = 4 stage 2, 3 stage 3 Control cats were neutered males (23, 40.4%), spayed females (18, 31.6%), intact males (10, 17.5%), and intact females (6, 10.5% supplement Amino acids and dipeptide were purchased from Nutriland Group, Inc. (Paramount, California, USA) and Dongyu USI (Irvine, California, USA), respectively. Each 300-mg dose included 25 mg L-arginine, 50 mg glycine, 50 mg L-glutamine, 25 mg L-histidine, 50 mg L-aspartic acid, 50 mg L-glutamic acid, and 50 mg L-carnosine. Cats were dosed twice daily. Each dose was mixed with 1.5 mL of water and was given by syringe directly into the subject's mouth or sprinkled on a small amount of food. (mg/ dL) n.n n.n n.n n.n n.n n.n n.n n.n n.n 2 " n.n n.n n.n n.n 3 " n.n n.n n.n n.n n.n n.n 4 " n.n n.n n.n n.n n.n n.n n.n n.n n.n 5 " n.n n.n n.n n.n n.n n.n n.n n.n 6 " n.n n.n n.n n.n n.n n.n n.n n.n n.n 7 " n.n n.n n.n n.n n.n 8 " n.n n.n n.n n.n n.n n.n n.n n.n 9 " n.n n.n n.n n.n n.n n.n n.n n.n n.n n.n 10 " n.n n.n n.n n.n n.n n.n n.n n.n 11 " n.n n.n n.n n.n n.n n.n n.n n.n 12 " n.n n.n n.n n.n n.n n.n n.n n.n n.n n.n 13 " n.n n.n n.n n.n n.n n.n n.n n.n n.n N…67 Entry points for each animal (Table 2A) were translated to Synchronized-Baseline Cohorts ( n.n n.n n.n n.n n.n n.n n.n n.n n.n n.n 2 " n.n n.n n.n n.n 3 " n.n n.n n.n n.n n.n n.n n.n n.n 4 " n.n n.n n.n n.n n.n n.n n.n n.n n.n n.n 5 " n.n n.n n.n n.n n.n n.n n.n n.n 6 " n.n n.n n.n n.n n.n n.n n.n n.n n.n 7 " n.n n.n n.n n.n n.n 8 " n.n n.n n.n n.n n.n n.n n.n n.n 9 " n.n n.n n.n n.n n.n n.n n.n n.n n.n n.n 10 " n.n n.n n.n n.n n.n n.n n.n n.n n.n n.n 11 " n.n n.n n.n n.n n.n n.n n.n n.n 12 " n.n n.n n.n n.n n.n n.n n.n n.n n.n n.n 13 " n.n n.n n.n n.n n.n n.n n.n n.n n.n n. 
BlooD sample collection
A blood sample (2.0-3.0 mL) was collected from the jug-ular or saphenous vein at each regularly-scheduled clinic visit and placed into a serum-separator tube. The whole 
laBoratory measurements
SCr and PHOS were measured approximately every 12 weeks, up to 104 weeks or death, whichever occurred first. Measurements were performed at Idexx or Antech laboratories using an Olympus AU2700 Chemistry Analyzer and Beckman-Coulter AU5431 Chemistry Analyzer, respectively.
SCr and PHOS coefficients of variation (CV), as determined by Idexx Laboratories, were 3.33%, 1.88% and 3.51%, 3.08% (low end, high end of normal range), respectively; and less than 3% for within-run samples at Antech Diagnostics, with a total precision of less than 5%.
Control group SCr and PHOS analyses were also performed by Antech Diagnostics and Idexx Laboratories, except for 1 clinic that used in-house instrumentation supplied by Antech Diagnostics. Some laboratory reports were more than 4 years old, so the CV of the instrumentation used then is not known. 
Bmp-7 mrna expression anD hrptec ViaBility assays

Bmp-7 mrna expression assay
Cells were cultured at 37°C, 5% CO2 in renal epithelial cell growth medium, and passaged to 2 96-well plates with a density of 4000 cells/well. After 24 h culture, varying concentrations of L-carnosine and AB070597 were added to each well and incubated for 6 days. 
statistical analysis
Baseline (time 0) was the moment each cat entered the study. SCr and PHOS measurements were assembled into synchronized-baseline OP cohorts to adjust for asynchronous baseline entry dates, with the result that earlier OP cohorts included more cats than later cohorts, as shown in Table 2 . Table 3 shows the number of treatment and control cats, versus length (OPs) of observation. ue was calculated for each OP as Week N-Week 0. Descriptive statistics were calculated by treatment and OP for each endpoint and for the change-from-baseline values for each endpoint. For each endpoint, the change-from-baseline values were modeled using a repeated measure analysis of covariance model, with an autoregressive first-order covariance structure. The following covariates were evaluated for inclusion in the repeated measures model: study (secondary-analysis data, included in Archer (2015), versus data from the current study), age, baseline value, gender, sterilized (spayed or neutered versus intact), and breed. The fixed effects for treatment, time, and treatment by time interaction were included in the model. LS-means for treatment and control SCr and IRIS stage change-from-baseline, for each OP, along with the 95% confidence intervals (CI) for the LS-means, were calculated. The same statistics for overall treatment over 104 weeks were calculated. In addition, the differences in LS-means between treatment and control for each OP and over the entire 104-week treatment period were determined, along with the corresponding 95% CIs and P-values for the differences. In addition, the counts and percentages for each IRIS stage for each OP were calculated for treatment and control groups. The P-value from the Cochran-Mantel-Haenszel (CMH) statistic, testing the alternative hypothesis that there was a linear association between treatment and stage, was calculated by OP. Normality assumptions were evaluated for each endpoint and, if the assumptions appeared violated, a sensitivity analysis was conducted using a ranked analysis of variance model like the original model used. The difference between these two models was that the changefrom-baseline was ranked within OP and then the model was fit on these ranked values. A two-sided, 2-sample t-test,with Satterthwaite approximation for unequal variances, was employed to compare the change-from-baseline body weights between treatment and controls. 
RESULTS
Results are reported as mean (SD); LS-mean (SEM); median (minimum, maximum).
scr
Mean SCr was 4.2 (2.66) mg/dL at week 0 for treatment cats, and 2.9 (0.89) mg/dL for control cats. Mean SCr was lower in the treatment group, when compared with controls, at all OP, from week 12 to week 104. Values are plotted in Figure 1 and Table 4 . Treated cats exhibited significantly reduced SCr from baseline at all OP (P <0.001 at 7 OP, P <0.004 at 1 OP), except for week 12 (P=0.054).
The overall difference at week 104, between treatment group and controls, was -0.5 (CI: -0.8, -0.2; P <0.001). There were some OPs where underlying normality assumptions may have been violated so a sensitivity analysis was performed on the ranked data. There was a significant difference for ranked data at all OPs including week 12. Thus, the data suggest that treatment significantly lowered SCr as compared with no treatment. The SCr LS-mean change-from-baseline over time is shown in Figure 2 and Table 5 . 
ops anD iris DistriBution
Mean IRIS Stage for treated cats was 2.8 (0.76) and 2.3 (0.68) at weeks 0 and 104, respectively (Figure 3 ). Stage 2, 3, and 4 cats were observed for 75 (32), 65 (34), and 39 (33) weeks, respectively (data not shown).
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Research Journal for Veterinary Practitioners June 2019 | Volume 7 | Issue 2 | Page 45 Mean IRIS Stage for controls was 2.3 (0.57) and 2.9 (0.88) at weeks 0 and 104, respectively (Figure 3 ). Stage 2, 3, and 4 cats were observed for 80 (27), 66 (28), and 65 (57) weeks, respectively (data not shown). 
iris stage
A comparison of averages showed that treated cats started at a numerically higher mean SCr and IRIS stage compared with controls. At week 12, treatment group stage declined whereas control group values increased ( Figure 3) . As time progressed, a gradual shift in the treatment group to lower mean IRIS stage compared with controls was observed. A CMH statistic test for linear association between treatment and reduced disease stage was significant at baseline, with the treatment group having higher stage values than the control group. At weeks 24, 48, 60, 72, 84, 96 , and 104 a significant linear association was observed between treatment and disease stage, with lower disease stage values observed in the treated cats compared with controls (Table 6 ). When IRIS Stage was expressed as LS-mean changefrom-baseline, weeks 12, 24, 36, 48, 60, 72, 84, 96 , and 104 showed significant reductions (P = 0.006 at week 12, P<0.001 weeks 24 to 104) as shown in Figure 4 and Table 7. The overall difference at week 104, between treatment and controls was -0.2 (CI: -0.3, -0.1; P <0.001). The treated group showed negative LS-mean change in IRIS
Research Journal for Veterinary Practitioners
June 2019 | Volume 7 | Issue 2 | Page 46 At baseline, the control group had a larger proportion of cats classified as IRIS Stage 2 (68.4 %) than did the treat ment group (40.3%). At all subsequent OP the proportion of cats classified as IRIS Stage 2 was greater in treated cats compared with controls, as shown in Figure 5 . Controls moved from predominantly Stage 2 to predominantly Stages 3 and 4 at week 104, whereas treated cats moved from a nearly equal distribution between Stages 2 and 3 to mostly Stage 2, with a small percentage of Stage 3 and 4 cats at week 104. Cats returned to IRIS Stage 1 only in the treatment group. Figures 5, 6, and 7 and Table 8 show the distribution of animals in each IRIS stage versus time. phos Treated cats showed an overall LS-mean PHOS difference at 104 weeks, when compared with controls, of -0.3 (CI: -1.2, 0.6; P = 0.5; data not shown). However, treatment group mean and median PHOS declined from baseline NE US
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safety anD palataBility
The cell viability assay revealed no cytotoxicity to hRPTEC when exposed to AB070597 for 72 h at 37°C, over the concentration range (100. 00, 50.00, 25.00, 12.50, 6.25, 3.13, 1.56, 0.78, 0 .39, and 0.2 ug/mL), as shown in Figure  10 ; therefore, no IC50 was calculated. Treated cats accepted AB070597 as a single oral dose and on food. Treatment diaries were not used in this study, but there were no reports of digestive distress or diarrhea. Some cats displayed symptoms consistent with CKD, but no observed adverse effects attributable to supplementation were reported by owners or veterinarians. There were no adverse changes in serum chemistries or complete blood counts traceable to supplementation in treated cats (data not shown). 
BoDy Weight
Baseline body weights were recorded in 57 treated cats. Body weights were recorded in 41 of those cats at their final study-related clinic visit. Baseline and time-equivalent NE US
Academic Publishers
Research Journal for Veterinary Practitioners June 2019 | Volume 7 | Issue 2 | Page 48 body weights were available from medical records for 53 and 46 control group cats, respectively. Control group cats lost an average of 0.9 kg (P < 0.001), while cats in the treatment group showed a mean body weight change of 0.0 kg ( P < 0.001). Changes in body weight are shown in Table 9 . 
Bmp-7 mrna expression assay
Overall, BMP-7 mRNA fold-change increased with rising concentrations of AB070597 and L-carnosine. BMP-7 mRNA was increased and significantly different from controls in all culture wells, except 1, at all concentrations (P < 0.05) (supplemental data). Changes were small, however, and no significant trend was established. Table 10 and Figures 11 and 12 show the mean fold-change at varying concentrations. 
DISCUSSION
Current controversy exists over whether TDs provide adequate nutrition for CKD cats (Scherk and Laflamme, 2016) . Commercial TDs, with decreased protein, phosphorus, and increased carbohydrate percentages, were not fed in this study because they would have lowered baseline oral amino acid and phosphorus intake and prevented some cats from reaching their daily metabolic energy requirement (Salaun et al., 2017; Hewson-Hughes et al., 2011) . SCr was chosen as an indicator of renal function because it correlates strongly with disease severity (Elliott and Barber, 1998) . PHOS was selected because increased levels associated with accelerated disease progression and poor prognosis (Boyd et al., 2008) . The IRIS disease staging system was used because it is an accepted tool for categorizing disease stage and monitoring progression. Bodyweight was an important variable used as an estimate of protein oxidation and nitrogen balance.
Mean SCr dropped dramatically in treated cats from baseline to week 12 and continued a generally negative slope to week 104. Control cats experienced the opposite trend, with mean SCr rising from baseline through week 104. Treatment group median body weight, over the same time remained stable, which was likely the result of their diet providing adequate nutrition by not restricting protein and fat. Had treatment cats lost weight, there might be reason to question SCr improvement, but that was not the case.
There are biological mechanisms that might explain these differences: SCr correlates positively with increased plasma levels of the endogenous L-arginine derivatives, asymmetrical and symmetrical dimethylarginine, in cats with CKD ( Jepson et. al., 2008) . Both competitively block cellular uptake of L-arginine, the exclusive biological substrate for nitric oxide synthesis, thereby inhibiting its production. The pathogenic role of blocked nitric oxide synthesis in human CKD patients was discussed by Zoccali et al. (2001) and Bode-Boger et al. (2006) . In diverse models of renal disease, oral L-arginine supplementation consistently improves glomerular filtration rate (Klahr, 1999) .
Treatment resulted in significant improvements in mean IRIS stage at week 24 onward. Treatment also created significant improvements (P<0.001, except for week 12 [P = 0.006]) in LS-mean IRIS stage change-from-baseline compared with controls, suggesting that treatment arrested, and to some extent, reversed disease.The reduction in IRIS stages conflicts with those observed in cats treated with conventional therapies, whose stages increase with time.
Mean and median PHOS remained within reference range for both treatment and control groups through 104 weeks. There were, however, significant differences in change-from-baseline, with PHOS falling below baseline from week 12 through week 104 in the treatment group and PHOS rising from week 24 through 104 in con-
